Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. reports developments as a commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its recurring updates center on mitapivat, an oral pyruvate kinase activator marketed as PYRUKYND® and AQVESME™, including product revenue, U.S. and ex-U.S. commercialization, thalassemia approvals, and activity in pyruvate kinase deficiency, sickle cell disease, and other hemolytic anemias.
Company news also covers FDA interactions, supplemental application activity, conference presentations, and pipeline progress for tebapivat, a next-generation PK activator, and other rare disease programs. International commercialization themes include regulatory approvals and distribution activity in Gulf Cooperation Council markets through NewBridge Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ: AGIO) reported Q2 2025 financial results, highlighting $12.5 million in PYRUKYND net revenues, a significant increase from $8.6 million in Q2 2024. The company maintains a strong financial position with $1.3 billion in cash and equivalents.
Key developments include the pending FDA review of PYRUKYND's sNDA for thalassemia with a PDUFA date of September 7, 2025, and anticipated topline results from the RISE UP Phase 3 trial in sickle cell disease by year-end. The company reported a net loss of $112.0 million for Q2 2025, compared to $96.1 million in Q2 2024, with increased R&D expenses of $91.9 million and SG&A expenses of $45.9 million.
Notable operational progress includes 248 unique patients completing prescription enrollment forms and 142 patients currently on PYRUKYND therapy. The company also secured a European distribution agreement with Avanzanite Bioscience and received IND clearance for AG-236 in polycythemia vera treatment.
Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, will host its second quarter 2025 financial results conference call and webcast on July 31, 2025, at 8:00 a.m. ET.
The presentation will be available through the company's website investor section, with a replay accessible approximately two hours after the event.
Agios Pharmaceuticals (Nasdaq: AGIO), a leader in cellular metabolism and PK activation therapies, has appointed Dr. Jay Backstrom to its Board of Directors. Dr. Backstrom, who will serve on the Science and Technology Committee, brings extensive experience in advancing clinical programs and regulatory approvals, particularly in rare diseases.
Dr. Backstrom's recent roles include serving as President and CEO of Scholar Rock, where he led the company's spinal muscular atrophy program through Phase 3 development. His previous positions include Executive VP of Research and Development at Acceleron Pharma and Chief Medical Officer at Celgene Corporation, where he contributed to regulatory approvals in beta thalassemia and myelodysplastic syndromes.
Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and pyruvate kinase activation for rare diseases, has announced its upcoming participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The presentation is scheduled for June 9, 2025, at 8:40 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A replay will remain available on the company's website for a minimum of two weeks after the presentation.
Agios Pharmaceuticals (NASDAQ: AGIO) will present new data on its pyruvate kinase (PK) activators, mitapivat and tebapivat, at the 30th EHA Congress in Milan. Key highlights include:
The ACTIVATE-KidsT Phase 3 study of mitapivat in children with PK deficiency showed meaningful reduction in transfusion burden, though not meeting statistical criteria. The ESTIMATE Phase 2 trial demonstrated sustained three-year efficacy of mitapivat in sickle cell disease patients. Preclinical data revealed tebapivat's potential in reducing red blood cell sickling in sickle cell disease samples.
The company will present 14 studies across various rare blood disorders including thalassemia, sickle cell disease, PK deficiency, and myelodysplastic syndromes at the conference scheduled for June 12-15, 2025.
Agios Pharmaceuticals (NASDAQ: AGIO), a biotechnology company focused on cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 21, 2025, at 8:00 AM ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A replay will remain available on the company's website for a minimum of two weeks after the presentation.
Agios Pharmaceuticals (NASDAQ: AGIO), a company focused on cellular metabolism and PK activation therapies for rare diseases, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 14, 2025, at 8:00 AM PT/11:00 AM ET. Investors and interested parties can access the live webcast through the Investors section of Agios' website under "Events & Presentations." A recording of the presentation will remain available on the company's website for a minimum of two weeks after the event.
Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has scheduled its first quarter 2025 financial results conference call and webcast for May 1, 2025, at 8:00 a.m. ET. The event will cover Q1 2025 financial performance and business updates.
The webcast will be available through the Investors section of Agios' website under Events & Presentations, with a replay accessible approximately two hours after the event.